Literature DB >> 19616059

The critical role of the bone microenvironment in cancer metastases.

Sandra Casimiro1, Theresa A Guise, John Chirgwin.   

Abstract

Bone metastatic disease is a late-stage event of many common cancers, such as those of prostate and breast. It is incurable and causes severe morbidity. Tumor and bone interact in a vicious cycle, where tumor-secreted factors stimulate bone cells, which in turn release growth factors and cytokines that act back on the tumor cells. Within the vicious cycle are many potential therapeutic targets for novel treatment of bone metastatic disease. Therapeutic strategies can be oriented to inhibit bone cells (osteoclasts and osteoblasts) or tumor responses to factors enriched in the bone microenvironment. Many publications, especially from pre-clinical animal models, show that this approach, especially combination treatments, can reduce tumor burden and tumor-derived bone lesions. This supports a novel paradigm: tumor growth can be effectively inhibited by targeting the bone and its microenvironment rather than the tumor itself alone.

Entities:  

Mesh:

Year:  2009        PMID: 19616059     DOI: 10.1016/j.mce.2009.07.004

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  55 in total

1.  CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone.

Authors:  Véronique Ouellet; Kerstin Tiedemann; Anna Mourskaia; Jenna E Fong; Danh Tran-Thanh; Eitan Amir; Mark Clemons; Bernard Perbal; Svetlana V Komarova; Peter M Siegel
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.

Authors:  Bhavani Krishnan; Thomas L Smith; Purnima Dubey; Michael E Zapadka; Frank M Torti; Mark C Willingham; E Ann Tallant; Patricia E Gallagher
Journal:  Prostate       Date:  2012-05-29       Impact factor: 4.104

Review 3.  Bone metastasis and the metastatic niche.

Authors:  Guangwen Ren; Mark Esposito; Yibin Kang
Journal:  J Mol Med (Berl)       Date:  2015-08-15       Impact factor: 4.599

Review 4.  Metastasis Organotropism: Redefining the Congenial Soil.

Authors:  Yang Gao; Igor Bado; Hai Wang; Weijie Zhang; Jeffrey M Rosen; Xiang H-F Zhang
Journal:  Dev Cell       Date:  2019-05-06       Impact factor: 12.270

5.  TGFβ-dependent induction of interleukin-11 and interleukin-8 involves SMAD and p38 MAPK pathways in breast tumor models with varied bone metastases potential.

Authors:  Janhavi Gupta; John Robbins; Tamas Jilling; Prem Seth
Journal:  Cancer Biol Ther       Date:  2011-02-01       Impact factor: 4.742

Review 6.  Purinergic signalling in the musculoskeletal system.

Authors:  Geoffrey Burnstock; Timothy R Arnett; Isabel R Orriss
Journal:  Purinergic Signal       Date:  2013-08-14       Impact factor: 3.765

7.  Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data.

Authors:  Brendan Boyce; Lianping Xing
Journal:  Clin Investig (Lond)       Date:  2011-12-01

8.  Breast cancer at bone metastatic sites: recent discoveries and treatment targets.

Authors:  Osama Hussein; Svetlana V Komarova
Journal:  J Cell Commun Signal       Date:  2011-01-19       Impact factor: 5.782

9.  Multimodality imaging of tumor and bone response in a mouse model of bony metastasis.

Authors:  Benjamin A Hoff; Komal Chughtai; Yong Hyun Jeon; Kenneth Kozloff; Stefanie Galbán; Alnawaz Rehemtulla; Brian D Ross; Craig J Galbán
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

10.  Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors.

Authors:  Antonella Chiechi; Chiara Novello; Giovanna Magagnoli; Emanuel F Petricoin; Jianghong Deng; Maria S Benassi; Piero Picci; Iosif Vaisman; Virginia Espina; Lance A Liotta
Journal:  Clin Cancer Res       Date:  2013-03-14       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.